Innovative methodology for small populations research
The HEALTH.2013.4.2-3 call identifies a need for new or improved statistical methodology for clinical trials for the efficient assessment of safety and/or efficacy of treatment for small population groups. This project brings tog...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
IDEAL
Integrated DEsign and AnaLysis of small population group tri...
4M€
Cerrado
MTM2015-64465-C2-1-R
METODOS ESTADISTICOS PARA ENSAYOS CLINICOS, PATRONES DE CENS...
255K€
Cerrado
BBMRI-LPC
BBMRI Large Prospective Cohorts
11M€
Cerrado
MTM2012-38067-C02-01
METODOS AVANZADOS EN ESTUDIOS DE SEGUIMIENTO: DISEÑO DE ENSA...
73K€
Cerrado
INVENTS
Innovative designs, extrapolation, simulation methods and ev...
6M€
Cerrado
MTM2014-55372-P
SELECCION DE MODELOS, META-ANALISIS Y COSTE-EFECTIVIDAD
24K€
Cerrado
Información proyecto InSPiRe
Líder del proyecto
UNIVERSITY OF WARWICK
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
3M€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
The HEALTH.2013.4.2-3 call identifies a need for new or improved statistical methodology for clinical trials for the efficient assessment of safety and/or efficacy of treatment for small population groups. This project brings together international experts in innovative clinical trial design methodology in these specific areas along with key stakeholders including regulatory authorities, industry, clinicians and patient groups to address this need. Our aim is the development novel methodology for the design and analysis of clinical trials in small populations. We will focus on four specific areas where we believe there are particular challenges: (i) early phase dose-finding studies in small populations, (ii) decision-theoretic methods for clinical trials in small populations, (iii) confirmatory trials in small populations and personalised medicines, (iv) use of evidence synthesis in the planning and interpretation of clinical trials in small populations and rare diseases.
We will build on recent research advances, of our own and of others in this area. In the rare disease setting, we will focus on Bayesian and decision-theoretic methods that formally enable comparison of the gain in information with the cost, both in economic and opportunity terms, of clinical experimentation, and assess how information from outside the trial can formally be incorporated in the design and decision-making processes. In the personalised medicine setting, we will develop methods that allow evaluation of efficacy in a number of sub-populations simultaneously in a confirmatory clinical trial without any reduction in scientific or statistical rigour.